RELAY THERAPEUTICS INC. - COMMON STOCK

Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights

27 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

19 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations

18 Apr 2023 09:40:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR

06 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

01 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

23 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

16 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day

02 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

07 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

03 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

27 Oct 2022 15:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference

26 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Pricing of Public Offering of Common Stock  

12 Sep 2022 20:30:51 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Proposed Public Offering of Common Stock

12 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease

11 Sep 2022 08:45:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

18 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

04 Aug 2022 15:05:03 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

28 Jul 2022 15:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

27 Jun 2022 05:00:00 By Nasdaq GlobeNewswire